Comparison of high titer Edmonston-Zagreb, Biken-CAM and Schwarz measles vaccines in Peruvian infants

Pediatric Infectious Disease Journal

Volumn 11, Issue 10, 1992, Pages 822-827

  Berry, Susan ^a   Hernandez, Herminio ^b   Kanashiro, Rosa ^b   Campos, Miquel ^b   Azabache, Veronica ^b   Gomez, Grimanesa ^b   Gutierrez, Manuel ^b   Weirs, Brook ^a   De quadros, Ciro ^c   Halsey, Neal ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c PAN AMERICAN HEALTH ORGANIZATION   (United States)

Author keywords

Biken CAM; Edmonston Zagreb; Immune response; Immunization; Maternal antibodies; Measles vaccine; Peru

Indexed keywords

MEASLES ANTIBODY; MEASLES VACCINE; NEUTRALIZING ANTIBODY;

AGE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONJUNCTIVITIS; COUGHING; DIARRHEA; DOSE CALCULATION; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES VACCINATION; PERU; PRIORITY JOURNAL; RASH; SAFETY; VIRUS STRAIN;

ANTIBODIES, VIRAL; COMPARATIVE STUDY; HUMAN; INFANT; MEASLES VACCINE; PERU; SPECIES SPECIFICITY; SUPPORT, NON-U.S. GOV'T; VACCINATION;

EID: 0026686759     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/00006454-199210000-00003     Document Type: Article

References (43)

1. Aabv P. Malnutrition and overcrowding/intensive exposure in severe measles infection: review of community studies. Rev Infect Dis 1988;10:478-91.
2. Assad F. Measles: summary of worldwide impact. Rev Infect Dis 1988;5:452-9.
3. Borgono JM. Current impact of measles in Latin America. Rev Infect Dis 1988;5:417-21.
4. Feachem RG, Koblinsky MA. Interventions for the control of diarrheal disease. Bull WHO 1988;61:641-52.
5. Henderson RH, Keja J, Hayden G, Galazka A, Clements J, Chan C. Immunizing the children of the world: progress and prospects. Bull WHO 1988;66:585-48.
6. Loening UE Coovadia HM. Age-specific occurrence rates of measles in urban, periurban, and rural environments and implication for time of vaccination. Lancet 1983;2:324-6.
7. Dabis F, Sow A, Waldman RJ, et al. The epidemiology of measles in a partially vaccinated population in an African city: implications for immunization programs. Am J Epidemiol 1988; 127:171-8.
8. Taylor WR, Mambu RK, Ma-Disu M, Weinman JM. Measles control efforts in urban Africa complicated by high incidence of measles in the first year of life. Am J Epidemiol 1988;127: 788-94.
9. Albrecht P, Ennis FA, Saltzman E.J, Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanisms of vaccine failure. J Pediatr 1977;91:715-8.
10. Black FL, Berman LL, Borgon JM, et al. Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody. Am J Epidemiol 1986;124:442-52.
11. Halsey NA, Boulos R, Mode F, et al. Response to measles vaccine in Haitian infants 6 to 12 months of age: influence of maternal antibodies, malnutrition and concurrent illnesses. N Engl J Med 1985;313:544-9.
12. Halsey NA. The optimal age for administration of measles vaccine in developing countries. In: Halsey NA, de Quadros C, eds. Recent advances in immunization. PAHO Sci Pub 451. 1983: Washington, DC: Pan American Health Organization, 4-13.
13. Ministries of Health of Brazil, Chile, Costa Rica and Ecuador and PAHO. Seroconversion rates and measles antibody titers induced by measles vaccination in Latin American children 6-12 months of age. Rev Infect Dis 1983;5:596-604.
14. Muhimble Medical Center, United Republic of Tanzania. Seroconversion after measles immunization. Wkly Epidemiol Rec 1981;56:234-7.
15. de Castro FJ, Valdespino Gomez JL, Diaz Ortega JL, Zarate Aquino L. Diploid cell measles vaccine. JAMA 1986;256:714.
16. Ikic D, Juzbasic M, Beck M, Hrabar A, Cimber-Schneider T. Attenuation and characterization of Edmonston-Zagreb measles virus. Ann Immun Hung 1972;12:175-81.
17. Job JS, Halsey NA, Boulos R, et al. Successful immunization of infants at 6 months of age with high dose Edmonston-Zagreb measles vaccine. Pediatr Infect Dis J 1991;10:303-11.
18. Khanum SGH, Uddin N, Garelick H, Mann G, Tomkins A. Comparison of Edmonston-Zagreb and Schwarz strains of measles vaccine given by aerosol or subcutaneous injection. Lancet 1987;1:150-3.
19. Markowitz LE, Sepulveda J, Diaz-Ortega JL, et al. Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med 1990; 322:580-7.
20. Sabin AB, Flores Arechiga A, de Castro FJ, Sever JL, Sackorch M, Albrecht P. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine: I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA 1983;249:2651-62.
21. Sabin AB, Flores Arechiga A, de Castro FJ, Albrecht P, Sever JL, Sackarch M. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine: II. Vaccine comparisons and evidence for multiple antibody response. JAMA 1984;251:2363-71.
22. Tidjani O, Guerin N, Lecam N, et al. Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccines strains given at ages 4-5 and 8-10 months. Lancet 1989;2: 1357-60.
23. Whittle HC, Campbell H, Rahman S, Armstrong JRM. Antibody persistence in Gambian children after high-dose Edmon-ston-Zabreb measles vaccine. Lancet 1990;336:1046-8.
24. Whittle HC, Hanlon P, O’Neill K, et al. Trial of high dose Edmonston-Zagreb measles vaccine in the Gambia: antibody response and side-effects. Lancet 1988;2:811-4.
25. Whittle HC, Mann G, Eccles M, et al. Effects of dose and strain of vaccine on success of measles vaccination in infants aged 4-5 months. Lancet 1988;1:963-6.
26. Whittle HC, Rowland MG, Mann GF, Lamb WH, Lewis RA. Immunization of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine. Lancet 1984;2:834-7.
27. Expanded Programme on Immunization. Global Advisory Group. Wkly Epidemiol Rec 1990;65:5-11.
28. Isomura S, Morishima T, Nishikawa K. A long term follow-up study of the efficacy of further attenuated live measles vaccine, Biken CAM vaccine. Biken J 1986;29:19-26.
29. Mirchamsy H, Shafyi A, Bahrami S, et al. A comparative field trial of five measles vaccines produced in human diploid cell, MRC-5. J Biol Stand 1977;5:1-18.
30. Mirchamsy H, Shafyi A, Bassali Y, Bahrami S, Nazari F. A comparative study of two live measles vaccines in Iran. Arch Inst Razi 1971;23:1-10.
31. Sangkawibha N, Tuchinda P, Bukkavesa S, Osatanora F, Okono Y. Comparative study on two further attenuated live measles virus vaccines, “CAM” and “Moraten.” Biken J 1971;14:77-9.
32. Ueda S, Takahashi M, Minekawa Y, et al. Studies on further attenuated live measles vaccine: II. Correlation between the titer of the vaccine, the antibody response and clinical reactions. Biken J 1970;13:117-20.
33. Gendrel D, Garin D, Dutailly C, et al. Immunization of infants with high doses of Schwartz measles vaccine. Pediatr Infect Dis J 1988;7:523-5.
34. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Meth 1981;3:251-60.
35. Vaisberg A, Alvarez JO, Hernandez H, Guillen D, Chu P, Colarossi A. Loss of maternally acquired measles antibodies in well-nourished infants and response to measles vaccination, Peru. Am J Public Health 1990;80:736-8.
36. Chen R, Mofenson L, Albrecht P, Page P, Orenstein W, Etkind P. Protective measles antibody titers in college students. Presented at the 35th Annual Epidemic Intelligence Service Conference, Atlanta, G A, April 14-18, 1986.
37. WHO Working Group. Use and interpretation of anthropometric indicators of nutritional status. Bull WHO 1986;64:929-48.
38. Armitage P. Statistical methods in medical research. Cambridge, United Kingdom: Oxford University Press, 1971.
39. Sokal RR, Rohlf FJ. Biometry. San Francisco: Freeman, 1981.
40. Sabin AB, Albrecht P, Takeda AK, Ribeiro EM, Veronesi R. High effectiveness of aerosolized chick embryo fibroblast measles vaccine in 7 month old and older infants. J Infect Dis 1985; 152:1231-7.
41. Wallace RB, Landrigan PJ, Smith EA, Pifer J, Teller B, Foster SO. Trial of a reduced dose of measles vaccine in Nigerian children. Bull WHO 1976;53:361-4.
42. Garenne M, Leroy O, Beau JP, Sene I. Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet 1991;338:903-7.
43. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: réévaluation of protective titers. J Infect Dis 1990; 162: 1036-42.